Led by Dr. Preet Chaudhary our cancer researchers are developing a new, improved type of CAR T-cell immunotherapy called Synthetic Immune Receptor (SIR-T) therapy
In a post by on Linkedin, it says, “Led by Dr. Preet Chaudhary, member of the USC Norris Tumor Microenvironment Program and director of the USC Norris Comprehensive Cancer Center’s Blood and Marrow Transplant and Cell Therapy program, our cancer researchers are developing a new, improved type of CAR T-cell immunotherapy called Synthetic Immune Receptor (SIR-T) therapy. Due in part to seven research grants — totaling nearly 9 million dollars recently awarded to Dr. Chaudhary’s laboratory by California Institute for Regenerative Medicine, Department of Defense, and Wright Foundation — the USC Norris Blood and Marrow Transplant and Cell Therapy Program is planning to launch SIR-T therapy human clinical trials for blood, prostate, ovarian, skin, kidney, lung, breast, brain, liver, pancreatic and gastrointestinal cancers in the next few years.”
Learn more here: https://lnkd.in/gjjvz3Dd.